Health Canada Clears Fotona Dynamis for Stress Urinary Incontinence (SUI) and Vulvovaginal Atrophy (VVA) / Genitourinary Syndrome of Menopause (GSM)

Food and Healthcare Press Releases Wednesday August 28, 2019 11:24
LJUBLJANA, Slovenia--28 Aug--PRNewswire/InfoQuest
Fotona's Cutting Edge Dynamis Laser System Earns Industry First Clearance

In an industry first achievement, Fotona's Dynamis Laser System received clearance by Health Canada, Canada's Food and Drugs Act and Regulations Agency, to treat stress urinary incontinence (SUI) and vulvovaginal atrophy (VVA) / genitourinary syndrome of menopause (GSM). Treatment for these conditions can be achieved by using the proprietary Fotona SMOOTH(R) Er:YAG modality and robotic G-Runner and G-set handpieces and speculums, which were specially designed for ease of use and precision during intravaginal treatments. After extensive review of detailed documentation and published studies performed with Fotona's Dynamis laser system, clearance was granted by Health Canada, further validating Fotona's commitment to evidence-based medicine.

The patented Fotona SMOOTH(R) technology holds a very unique position in the market, making it a leading solution for providers and patients. Unlike competing laser technologies, Fotona SMOOTH(R) is completely non-ablative and combines an additional superficial heat-shocking mechanism of tissue regeneration with a unique self-regulating safety feature. These dual-tissue regeneration characteristics of Fotona SMOOTH(R) are believed to be responsible for the reported extraordinary safety and efficacy of Fotona's Er:YAG lasers when used for thermotherapy of the vaginal wall to alleviate symptoms of stress urinary incontinence and genitourinary syndrome of menopause.

Combining two complementary wavelengths, 1064nm and 2940nm, with Fotona's proprietary pulse characteristics, the Dynamis PRO is a multi-purpose system that is capable of performing a wide range of applications, not only in gynecology but also in surgery and aesthetics. The robotic G-Runner enables revolutionary intravaginal treatments with ease and precision. This innovative technology is why providers choose Fotona to achieve optimal outcomes for their patients and further establish their practices as best-in-class.

This clearance is yet another achievement for Fotona, marking the first of its kind in the laser industry. Known globally for its continuous dedication to developing industry-leading technology, Fotona has earned its place as the gold standard in laser technology for health providers and patients around the world.

ABOUT FOTONA

Fotona ( www.fotona.com ) has sold over 30,000 lasers around the world, with direct sales in the U.S. and distribution in over 60 countries. Fotona produces award-winning lasers in dentistry, aesthetics, dermatology, gynecology & other medical fields. Fotona has one of the most highly educated workforces in the industry, with an exceptionally high number of PhDs specializing in laser and medical technology. Strong R&D capabilities have always been a key competitive advantage of the company, resulting in many patented solutions, including the Optoflex(R) articulated arm, Quantum Square Pulse and Variable Square Pulse technologies, Fotona SMOOTH(R) mode, Vacuum Cell technology, and more.

The company manufactures all of its laser systems in-house, ensuring that each system is of the highest quality, reliability, ease-of-use and durability, in compliance with all applicable international standards. When you choose Fotona, you choose a company that aims to continuously Choose Perfection to meet the needs of a highly demanding marketplace.

Logo - https://mma.prnewswire.com/media/966027/Fotona_Logo.jpg
CONTACT:
Ladislav Grad
info@fotona.com
(+386)-1-5009-100

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics